Valuation: RVL Pharmaceuticals plc

Market Cap 3L 3L 3L 2L 5L 3.19Cr 5L 31.88L 12.51L 1.59Cr 12.55L 12.28L 5.33Cr P/E 2021
-1.12x
P/E 2022 -1.95x
Enterprise Value 1.33Cr 1.15Cr 1.07Cr 98.66L 1.86Cr 126.77Cr 1.89Cr 13Cr 4.97Cr 63Cr 4.99Cr 4.88Cr 211.63Cr EV / Sales 2021
5.55x
EV / Sales 2022 2.49x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0.5
5 years 0
Extreme 0
4.38
10 years 0
Extreme 0
9.9
Manager TitleAgeSince
Chief Operating Officer 44 01/01/2016
Human Resources Officer - 01/01/2016
Date Insider Type Main position Quantity % Market Cap.
19/10/23
Altchem Ltd.
SellCompany 1,41,22,659 12.6767%
19/10/23
Altchem Ltd.
SellCompany 1,41,22,659 12.6767%
18/10/23
Altchem Ltd.
SellCompany 34,21,537 3.0712%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 111
-1.40%+2.59%-1.71%+11.28% 4.85TCr
-2.41%-0.90%+411.96%+495.33% 3.99TCr
-1.16%+12.96%+28.81%+7.25% 3.87TCr
-1.88%-3.03%+5.69%+53.00% 3.51TCr
-1.74%+5.12%+14.44%+41.77% 2.98TCr
-2.85%-3.92% - - 1.61TCr
-0.21%-4.04%+36.40%+125.75% 1.61TCr
-0.64%+2.65%+3.40%+13.11% 1.36TCr
-1.19%-1.32%-1.73%-34.37% 1.26TCr
Average -1.35%+0.95%+62.16%+89.14% 2.5TCr
Weighted average by Cap. -1.60%+2.03%+79.78%+108.61%

Financials

2021 2022
Net sales 1.75Cr 1.52Cr 1.42Cr 1.3Cr 2.46Cr 167.07Cr 2.49Cr 17Cr 6.55Cr 83Cr 6.57Cr 6.43Cr 278.89Cr 4.97Cr 4.32Cr 4.02Cr 3.69Cr 6.98Cr 474.64Cr 7.08Cr 47Cr 19Cr 236.3Cr 19Cr 18Cr 792.34Cr
Net income -6.49Cr -5.64Cr -5.25Cr -4.82Cr -9.11Cr -619.73Cr -9.25Cr -62Cr -24Cr -308.53Cr -24Cr -24Cr -1.03TCr -5.17Cr -4.49Cr -4.18Cr -3.84Cr -7.25Cr -493.45Cr -7.36Cr -49Cr -19Cr -245.66Cr -19Cr -19Cr -823.75Cr
Net Debt 72.01L 62.6L 58.27L 53.49L 1.01Cr 69Cr 1.03Cr 6.87Cr 2.7Cr 34Cr 2.7Cr 2.64Cr 114.75Cr 1.29Cr 1.13Cr 1.05Cr 96.17L 1.82Cr 123.58Cr 1.84Cr 12Cr 4.85Cr 62Cr 4.86Cr 4.76Cr 206.3Cr
Logo RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.
Employees
125
Date Price Change Volume
31/26/31 $0.000001 -.--% 3,000
27/26/27 $0.000001 -.--% 10,000
  1. Stock Market
  2. Stocks
  3. RVLP.Q Stock